Cancro alla vescica

In developed countries 90% of bladder cancers are transitional cell carcinomas.¹ Squamous cell carcinomas make up most of the remainder.

Cancer arising from the transitional cells of the mucosal urothelium may present as a non-invasive, papillary tumour protruding from the mucosal surface, or as a solid, non-papillary tumour that invades the bladder wall and has a high propensity for metastasis. The non-papillary tumours originate from in situ dysplasia.

Epidemiologia²

• Bladder cancer is the 11th most common cancer in the UK, accounting for 3% of all new cancer cases.

• Incidence rates for bladder cancer in the UK are highest in people aged 85 to 89. 56% of all new bladder cancer cases in the UK are diagnosed in people aged 75 and over.

• Since the early 2000s, bladder cancer incidence rates have decreased by 23% in the UK. Bladder cancer incidence rates are projected to fall by 14% in the UK between 2023-2025 and 2038-2040.

• Bladder cancer incidence rates in England in females are 47% higher in the most deprived quintile compared with the least, and in males are 23% higher in the most deprived quintile compared with the least.

• Incidence rates for bladder cancer are lower in the Asian and Black ethnic groups, compared with the White ethnic group, in England.

Risk factors for bladder cancer

• The main risk factor for bladder cancer is increasing age.

• About half of bladder cancers are caused by smoking. Tobacco smoke contains aromatic amines and polycyclic aromatic hydrocarbons, which are renally excreted.

• The risk of developing bladder cancer is 2-6 times greater in smokers than in non-smokers.³

• Occupational exposure to aromatic amines, polycyclic aromatic hydrocarbons and chlorinated hydrocarbons is the second most important risk factor for bladder cancer, accounting for about 10% of all cases. This type of occupational exposure occurs mainly in industrial plants processing paint, dye, metal and petroleum products. NB: in developed industrial settings, these risks have been reduced by work safety guidelines so that chemical workers no longer have a higher incidence of bladder cancer compared to the general population.

• Other risk factors include industrial exposure to aromatic amines in dyes, paints, solvents, leather dust, inks, combustion products, rubber and textiles.

• Radiation to the pelvis and cyclophosphamide are risks.

• Squamous cell tumours usually follow chronic inflammation from stones or indwelling catheters.

• In developing countries, particularly the Middle East, squamous cell carcinoma related to schistosomiasis accounts for around 80% of cases of bladder cancer.

• The presenting feature is painless haematuria that is gross in 80-90%. There is usually no abnormality on standard physical examination. Painless haematuria must be treated as malignancy of the urinary tract until proved otherwise.

• Advanced disease may cause voiding symptoms, although these can even be produced by carcinoma in situ (CIS).

• Although most diagnosed cases of muscle-invasive bladder cancer present as primary invasive bladder cancer, up to 15% of patients have a history of non-muscle-invasive bladder cancer.⁴

• Women are more likely to present with muscle invasive disease.⁵

• At diagnosis, only about 5% of patients have metastatic disease, usually to lymph nodes, lung, liver, bone and central nervous system. Around 30% have involvement of the muscle layer.⁶ Around 70% have superficial disease, of which 10% is CIS.

NB: microscopic (non-visible) haematuria is still associated with around half the risk of bladder cancer seen with visible haematuria. It is therefore very important that patients with microscopic haematuria, especially those aged over 60 years, be referred for assessment for bladder cancer.⁷

Current recommendations from the National Institute for Health and Care Excellence (NICE) are for the following patients to be referred urgently for a urological assessment:

• Adults over 45 years who have unexplained visible haematuria without urinary tract infection.

• Adults over 45 years with visible haematuria that persists or recurs after successful treatment of urinary tract infection.

• Adults aged 60 and over who have unexplained non-visible haematuria and either dysuria or a raised white cell count on a blood test.

A non-urgent referral for bladder cancer is recommended for those people aged 60 and over with recurrent or persistent unexplained urinary tract infection.

• Haemorrhagic cystitis.

• Nefrolitiasi.

• Renal cancer.

• Urethral trauma.

• Infezione del tratto urinario.

The diagnosis mainly depends on the cystoscopic examination of the bladder, biopsy and urine cytology:

• Urinalysis including culture should be performed to exclude infection.

• FBC should be arranged to exclude anaemia.

• Renal function tests and electrolytes should be arranged.

• Urine cytology may be helpful but negative results do not exclude disease.

• CT or MRI staging should be considered before transurethral resection of bladder tumour (TURBT) if muscle-invasive bladder cancer is suspected.⁹

• Cystoscopy permits direct inspection of the bladder and biopsy of suspicious lesions.

• NICE recommends that white light-guided TURBT should be offered with one of photodynamic diagnosis, narrow‑band imaging, cytology or a urinary biomarker test (such as UroVysion® using fluorescence in-situ hybridisation (FISH), ImmunoCyt® or a nuclear matrix protein 22 (NMP22) test) to people with suspected bladder cancer. This should be carried out or supervised by a urologist experienced in TURBT.⁹

• However, in practice urinary biomarkers are usually only used in research.

• Biopsy of the prostatic urethra is recommended for cases of bladder neck tumour, when bladder CIS is present or suspected, when there is positive cytology without evidence of tumour in the bladder, or when abnormalities of the prostatic urethra are visible.

The diagnosis of CIS¹⁰

• Urine cytology is important in the diagnosis and follow-up of Tis (see 'Staging', below) because of its high sensitivity and specificity (over 90%).

• As stated above, biopsy of the prostatic urethra is recommended when bladder CIS is present or suspected

• If equipment is available, fluorescence-guided biopsy should be performed when bladder CIS is suspected (for example, positive cytology, recurrent tumour with previous history of a high-grade lesion).

Investigations for staging the tumour

• T-staging: either MR imaging with fast dynamic contrast enhancement or CT with contrast enhancement is recommended for patients considered suitable for radical treatment.

• For patients with confirmed muscle-invasive bladder cancer, CT of the chest, abdomen and pelvis is the optimal form of staging, including CT urography for complete examination of the upper urinary tracts.⁶

The tumour, node and metastasis (TNM) classification is as follows :

• T - primary tumour:
  

  • Ta: non-invasive papillary carcinoma.

  • Tis: CIS; 'flat tumour'.

  • T1: il tumore invade il tessuto connettivo sottoepiteliale.

  • T2: tumour invades muscularis:
    

    • T2a: superficial muscle (inner half).

    • T2b: deep muscle (outer half).

  • T3: tumour invades perivesical tissue (beyond muscularis):
    

    • T3a: microscopically.

    • T3b: macroscopically (extravesical mass).

  • T4: tumour invades any of the following - prostate, uterus, vagina, pelvic wall, abdominal wall:
    

    • T4a: prostate, uterus, or vagina.

    • T4b: pelvic wall or abdominal wall.

• N - lymph nodes:
  

  • NX: i linfonodi regionali non possono essere valutati.

  • N0: no regional lymph node metastases.

  • N1: metastasis in a single lymph node in the true pelvis (hypogastric, obturator, external iliac, or presacral).

  • N2: metastases in multiple lymph nodes in the true pelvis (hypogastric, obturator, external iliac, or presacral).

  • N3: metastasis in common iliac lymph node(s).

• M - distant metastasis:

  • MX: metastasis not assessed.

  • M0: nessuna metastasi a distanza.

  • M1: metastasi a distanza.

There are many refinements on this system. One such refinement, which incorporates histological findings and tumour size, is described in the NICE guidelines.⁹

Non-invasive tumours⁹

• The management of non-muscle-invasive bladder cancer usually depends upon the risk category of the patient. The risk is either low, intermediate or high and depends upon the size of the cancer, the number of the cancers and the grade of the cancer. The method of calculating risk has been updated by the European Association of Urology and a calculator is available .

• The standard initial therapy for solitary Ta and T1 papillary bladder tumours is complete macroscopic transurethral resection (TUR) including a part of the underlying muscle. A second TUR should be considered if there is a suspicion that the initial resection was incomplete.

• TUR alone is only possible as a therapeutic option if tumour growth is limited to the superficial muscle layer and if re-staging biopsies are negative for residual tumour.¹⁰

• People with suspected bladder cancer should be offered a single dose of intravesical mitomycin C given at the same time as the first TURBT.

• People with newly diagnosed intermediate-risk non-muscle-invasive bladder cancer should be offered a course of at least six doses of intravesical mitomycin C.

• The choice of intravesical bacillus Calmette-Guérin (BCG) or radical cystectomy should be offered to people with high-risk non-muscle-invasive bladder cancer.

• Intravesical induction and maintenance immunotherapy with BCG is the preferred and most effective agent for patients with CIS and high-grade disease and reduces both recurrence and progression.¹¹

• The choice of treatment should be based on a full discussion which should include:

  • The type, stage and grade of the cancer, the presence of CIS, the presence of variant pathology, prostatic urethral or bladder neck status and the number of tumours.

  • Risk of progression to muscle invasion, metastases and death.

  • Risk of understaging.

  • Benefits of both treatments, including survival rates and the likelihood of further treatment.

  • Risks of both treatments.

  • Factors that affect outcomes (for example, comorbidities and life expectancy).

  • Impact on quality of life, body image and sexual and urinary function.

Invasive tumours⁹

• Neoadjuvant chemotherapy using a cisplatin combination regimen should be offered before radical cystectomy or radical radiotherapy to people with newly diagnosed muscle-invasive urothelial bladder cancer for whom cisplatin-based chemotherapy is suitable .

• Radical cystectomy is the preferred curative treatment for localised bladder neoplasms. Radical cystectomy includes removal of regional lymph nodes. The terminal ileum and colon are the intestinal segments of choice for urinary diversion:
  

  • Laparoscopic cystectomy is a safe, feasible and minimally invasive alternative to open radical cystectomy and is associated with fewer complications.¹²

  • Despite advances in perioperative care, radical cystectomy is associated with significant morbidity.¹³

• An orthotopic bladder substitute should be offered to male and female patients lacking any contra-indications and who have no tumour in the urethra and at the level of urethral dissection.

• Adjuvant cisplatin combination chemotherapy after radical cystectomy can be considered for people with muscle-invasive or lymph node-positive urothelial bladder cancer for whom neoadjuvant chemotherapy was not suitable (because muscle invasion was not shown on biopsies before cystectomy).

• The use of cisplatin-based neoadjuvant chemotherapy for bladder cancer has been shown to give a 9% absolute increase in five-year disease-free survival compared with radical cystectomy alone.⁴

• A radiosensitiser (such as mitomycin in combination with fluorouracil (5‑FU) or carbogen in combination with nicotinamide) should be used when giving radical radiotherapy for muscle-invasive urothelial bladder cancer.⁹

• External beam radiotherapy alone should only be considered as a therapeutic option when the patient is unfit for cystectomy or a multimodality bladder-preserving approach.⁶

• Neoadjuvant cisplatin-containing combination chemotherapy improves overall survival by 5-7% at five years, irrespective of the type of definitive treatment. However, neoadjuvant chemotherapy is not recommended in patients with poor performance status and impaired renal function.

• For patients with inoperable locally advanced tumours (T4b), primary radical cystectomy is not a curative option but a palliative cystectomy may be indicated for symptom relief.

Metastatic disease⁹

• The role of first-line chemotherapy should be discussed with people who have locally advanced or metastatic bladder cancer. The prognosis of their cancer and the advantages and disadvantages of the treatment options, including best supportive care, should be discussed.

• First-line treatment for 'fit' patients: use cisplatin-containing combination chemotherapy. Carboplatin and non-platinum combination chemotherapy is not recommended.

• First-line treatment in patients ineligible ('unfit') for cisplatin: use carboplatin combination chemotherapy or single agents, preferably with gemcitabine/carboplatin.

• In patients progressing after platinum-based combination chemotherapy for metastatic disease, second-line should be offered.

Avelumab per il trattamento di mantenimento del cancro uroteliale localmente avanzato o metastatico dopo chemioterapia a base di platino¹⁴

• Avelumab is recommended by NICE as an option for maintenance treatment of locally advanced or metastatic urothelial cancer that has not progressed after platinum-based chemotherapy in adults.

• Avelumab can only be used if it is stopped at five years of uninterrupted treatment or earlier if the disease progresses.

• Clinical trial evidence shows that if people take avelumab it takes longer for their cancer to get worse, and they live longer than if they have best supportive care.

• Avelumab meets NICE's criteria to be considered a life-extending treatment at the end of life.

Nivolumab per il trattamento adiuvante del cancro uroteliale invasivo ad alto rischio di recidiva¹⁵

• NICE has recommended nivolumab as an option for the adjuvant treatment of muscle-invasive urothelial cancer that is at high risk of recurrence after radical resection in adults whose tumours express PD-L1 at a level of 1% or more.

• It can only be used if adjuvant treatment with platinum-based chemotherapy is unsuitable.

• Clinical trial evidence shows that adjuvant treatment with nivolumab reduces the risk of the cancer coming back but it is uncertain whether nivolumab increases how long people live as these data are currently unavailable.

Managing symptoms of locally advanced or metastatic cancer⁹

• Bladder symptoms:

  • Palliative radiotherapy may benefit those with symptoms of haematuria, dysuria, urinary frequency or nocturia caused by advanced bladder cancer.

• Loin pain and symptoms of acute kidney injury:

  • Percutaneous nephrostomy or retrograde stenting (if technically feasible) may be an option for people with locally advanced or metastatic bladder cancer and ureteric obstruction who need treatment to relieve pain, treat acute kidney injury or improve renal function before further treatment.

• Intractable bleeding:

  • Hypofractionated radiotherapy or embolisation may be considered for people with intractable bleeding caused by incurable bladder cancer.

• Pelvic pain:

  • Hypofractionated radiotherapy, nerve block or palliative chemotherapy may be options for those with pelvic pain caused by incurable bladder cancer.

• Patients with non-invasive bladder tumours (TaT1) need to be followed up after completion of treatment, because of the risk of recurrence and progression.

• Those people who have had low-risk non-muscle-invasive bladder cancer and who have no recurrence of the bladder cancer within 12 months can be discharged to primary care. Those people with intermediate-risk non-muscle-invasive bladder cancer should be offered cystoscopic follow-up at three, nine and 18 months, and once a year thereafter. Those people with high-risk non-muscle-invasive bladder cancer should be offered cystoscopic follow-up every three months for the first two years, then every six months for the following two years, then once a year thereafter.

• The result of the first cystoscopy after TUR at three months is a very important prognostic indicator for recurrence and progression.

• After radical cystectomy a follow-up protocol should consist of:

  • Monitoring of the upper tracts for hydronephrosis, stones and cancer, using imaging and glomerular filtration rate (GFR) estimation at least annually.

  • Monitoring for local and distant recurrence using CT of the abdomen, pelvis and chest six, 12 and 24 months after radical cystectomy.

  • Monitoring for metabolic acidosis and B12 and folate deficiency at least annually.

  • Urethral washing for cytology and/or urethroscopy annually for five years to detect urethral recurrence for men with a defunctioned urethra.

• After radical radiotherapy a follow-up protocol should involve:

  • Rigid cystoscopy three months after radiotherapy has been completed, followed by either rigid or flexible cystoscopy every three months for the first two years, then every six months for the next two years, then every year thereafter, according to clinical judgement and the person's preference.

  • Upper tract imaging every year for five years.

  • Monitoring for local and distant recurrence using CT of the abdomen, pelvis and chest six, 12 and 24 months after radical radiotherapy has finished.

• Infezione del tratto urinario.

• Ritenzione urinaria.

• Hydronephrosis.

• Recurrence of tumour. The risk of upper urinary tract tumour recurrence increases in patients with multiple and high-risk bladder tumours.

• Increased risk of urethral transitional cell carcinoma.

• Complications of surgery include bowel obstruction, obstruction of the ureter, pielonefrite and infection of the wound.

• Radical cystectomy damages the S2,3,4 outlet and causes complete difficoltà erettile, although a nerve-sparing approach can reduce this to about half.

• Orthotopic bladders have a risk of incontinenza urinaria.

• 46.3% of people diagnosed with bladder cancer in England survive their disease for ten years or more. Bladder cancer ten-year survival in England is lower in females than males.

• 57.4% of people in England diagnosed with bladder cancer aged 15-54 survive their disease for ten years or more, compared with 31.5% of people diagnosed aged 75-99.

• For bladder cancer, like other cancer sites, survival trends reflect a combination of changes in treatment and stage distribution. These factors themselves can vary by age, sex and deprivation.

• The recurrence rate for superficial transitional cell cancer of the bladder is high (70% within five years). As many as 80% of patients have at least one recurrence.

• Patients with tumour recurrences within two years have an aggressive tumour and an increased risk of disease progression (especially with recurrences within 3-6 months).

• The most significant prognostic factors for bladder cancer are grade, depth of invasion, and the presence of CIS.

• Patients with superficial tumours have an excellent prognosis with five-year survival rates between 80-90%.

• Patients with muscle-invasive bladder cancer have five-year survival rates of between 30-60%.

• Prognosis for metastatic cancer is poor, with only 10-15% of patients living for five years after diagnosis.